National Physical Laboratory, Teddington, TW11 0LW, UK.
Department of Chemistry, University of Surrey, Guildford, GU2 7XH, UK.
Sci Rep. 2019 Jul 26;9(1):10884. doi: 10.1038/s41598-019-47463-3.
Four terbium radioisotopes (Tb) constitute a potential theranostic quartet for cancer treatment but require any derived radiopharmaceutical to be essentially free of impurities. Terbium-155 prepared by proton irradiation and on-line mass separation at the CERN-ISOLDE and CERN-MEDICIS facilities contains radioactive CeO and also zinc or gold, depending on the catcher foil used. A method using ion-exchange and extraction chromatography resins in two column separation steps has been developed to isolate Tb with a chemical yield of ≥95% and radionuclidic purity ≥99.9%. Conversion of terbium into a form suitable for chelation to targeting molecules in diagnostic nuclear medicine is presented. The resulting Tb preparations are suitable for the determination of absolute activity, SPECT phantom imaging studies and pre-clinical trials.
四种铽放射性同位素（Tb）构成了癌症治疗的潜在治疗诊断四元体，但需要任何衍生的放射性药物基本上不含杂质。在 CERN-ISOLDE 和 CERN-MEDICIS 设施中通过质子辐照和在线质量分离制备的铽-155含有放射性 CeO，并且根据所用的捕集箔，还含有锌或金。已经开发了一种使用离子交换和萃取色谱树脂的两步柱分离方法来分离 Tb，其化学收率≥95%，放射性核纯度≥99.9%。介绍了将铽转化为适合与诊断核医学中靶向分子螯合的形式。所得 Tb 制剂适用于绝对活度的测定、SPECT 体模成像研究和临床前试验。
